BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 "We are pleased with the positive feedback we continue to receive from physicians, caregivers, and patients about IGALMI™ for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. "Since our commercial launch and deployment of focused market-access strategy, we are continuing to build IGALMI brand equity. Our current ind ...